Q2 2026 Nutex Health Inc Earnings Call Transcript
Key Points
- Net income attributable to Nutex Health Inc (NUTX) surged 3100% to $112.6 million in the first half of 2026, driven by lower earnout expenses and reduced arbitration costs.
- Adjusted EBITDA increased 2% to $147.5 million for the first half of 2026, with Q2 alone up 25.7% year-over-year to $90 million.
- Hospital patient visits grew 6.2% in the first half of 2026, with same-hospital visits up 6.3% in Q2, reflecting strong operational execution.
- The renegotiated HaloMD agreement and reduced CMS IDR fees are expected to lower arbitration-related costs by 25-30% in future periods.
- Cash on hand grew to $207.1 million, and net cash from operating activities increased 40% to $109.7 million, providing strong liquidity for growth.
- Favorable court rulings in multiple states and the final IDR rule support the integrity of the arbitration process, benefiting Nutex Health Inc (NUTX)'s reimbursement outlook.
- The company is expanding its development pipeline with three new hospitals expected to open in 2026 and several more in 2027, including self-developed projects.
- Population Health Division revenue grew 15% in the first half of 2026, with most IPAs profitable and new IPAs in Dallas and San Antonio set to enroll patients in 2027.
- Operational efficiency improved, with facility-level costs as a percentage of revenue declining to 45.5% from 46.6% year-over-year.
- Patient satisfaction remains high with a 4.8-star Google rating, and employee turnover is low at 6.8%, supporting consistent care quality.
- Total revenue decreased 6.3% to $427.2 million in the first half of 2026, primarily due to timing differences in accrual-to-cash collections.
- Same-hospital revenue declined 6% in the first half of 2026, reflecting the normalization of revenue per visit after the initial IDR process boost in 2025.
- General and administrative expenses increased to 7.3% of revenue in the first half of 2026, up from 4.9% in the prior year period.
- The company still relies heavily on the IDR process, with 50-60% of claims submitted, and insurer behavior has not significantly improved despite favorable court rulings.
- In-network contract negotiations have shown only slight progress, with rates still below desired levels, limiting the potential for reduced reliance on arbitration.
- The Population Health Division's South Florida IPA remains slightly cash flow negative, indicating ongoing challenges in that market.
- The company faces execution risks with its accelerated development pipeline, including three hospital openings in the second half of 2026 and several more in 2027.
- Revenue per visit is expected to remain stable, but any significant fluctuations in collection rates or key metrics could impact future revenue recognition.
- The company's growth strategy involves self-financing real estate development, which could increase capital intensity and balance sheet risk.
- Despite lower IDR fees, the company still faces significant arbitration-related costs, and the pay-on-collection basis may delay cash flows from arbitration awards.
Greetings and welcome to the New Tax Health 2026 Second Quarter 10-Q Earnings Call.
(Operator Instructions)
It is now my pleasure to introduce Vivian Sanders, Corporate Director of Marketing. Please go ahead.
Good morning, everyone, and welcome to NewTex Health Inc.'s second quarter 2026 earnings call. My name is Vivian Sanders, and I'm happy to serve as your moderator today. We're truly grateful for your participation and your continued interest in our company as we share the highlights of another exceptional quarter.
Please note that this call is being recorded for future reference.
Joining me this morning are the key leaders driving New Text Health forward. Our Chairman and CEO, Dr. Tom Vo, our Chief Financial Officer, John Bates, our President, Dr. Warren Hassinian, and our Chief Operating Officer, Wes Bamberg. Together, they'll provide prepared remarks to give you a comprehensive view of our performance strategies and vision, after which we'll open the floor for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
